임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 1/2상모집 중· Malignant NeoplasmA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Lymphoma, Non-HodgkinA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
리드: 머크(MSD)
- 1/2상모집 중· Lung Neoplasm MalignantA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
리드: 머크(MSD)
- 1/2상모집 예정· Recurrent Respiratory Papillomatosis (RRP)Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*
협력: 머크(MSD)
- 1/2상모집 중· Locally Advanced or Metastatic Solid TumorsBC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Oesophageal Squamous Cell CarcinomaA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
리드: 머크(MSD)
- 1/2상모집 중· Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaA Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
협력: 머크(MSD)
- 1/2상모집 중· Small Cell Lung Cancer Extensive StageA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
리드: 머크(MSD)
- 1/2상모집 중· Bladder CancerA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
리드: 머크(MSD)
- 1/2상모집 중· Solid TumorsABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Esophageal Squamous Cell CarcinomaSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
리드: 머크(MSD)
- 1/2상모집 중· Cervical AdenocarcinomaExternal Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
협력: 머크(MSD)
- 1/2상모집 중· Castration-Resistant Prostatic CancerA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
리드: 머크(MSD)
- 1/2상모집 중· Malignant NeoplasmA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorsPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Ovarian Cancer RecurrentA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
리드: 머크(MSD)
- 1/2상모집 중· Bladder CancerEnfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorsA Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
리드: 머크(MSD)
- 1/2상모집 중· Non-Muscle Invasive Bladder CancerA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Melanoma MetastaticDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
협력: 머크(MSD)
- 1/2상모집 중· Gastrointestinal CancerStudy of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
리드: 머크(MSD)
- 1/2상모집 중· Non-small Cell Lung CancerA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· MSI-H/dMMR Gastroesophageal-junction CancerA Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
협력: 머크(MSD)
- 1/2상모집 중· B-cell Acute Lymphoblastic LeukemiaSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
리드: 머크(MSD)
- 1/2상모집 중· Gastroesophageal JunctionSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
리드: 머크(MSD)
- 1/2상모집 중· Extensive Stage-small Cell Lung CancerA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
리드: 머크(MSD)
- 1/2상모집 중· Colorectal CancerA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
리드: 머크(MSD)
- 1/2상모집 중· Prostatic Neoplasms, Castration-ResistantSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
리드: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Bladder CancerA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
리드: 머크(MSD) · 협력: 모더나
- 1/2상모집 중단 (진행 중)· Glioblastoma MultiformeT Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
협력: 머크(MSD)
- 1/2상모집 중· Metastatic Breast CancerA Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중· HPV Positive Oropharyngeal Squamous Cell CarcinomaSafety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
협력: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Solid TumorsBI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Metastatic Urothelial CarcinomaA Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
리드: 머크(MSD)
- 1/2상모집 중· Advanced Solid TumorPembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
협력: 머크(MSD)
- 1/2상모집 중· Esophageal Squamous Cell CarcinomaA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
리드: 머크(MSD)
- 1/2상모집 중· Solid Tumor, AdultA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
협력: 머크(MSD)
- 1/2상모집 중· Gastric or Gastroesophageal Junction AdenocarcinomaSpevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
협력: 머크(MSD)
- 1/2상모집 중· Solid TumorStudy of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Esophageal CancerOral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Advanced or Metastatic Solid TumorsA Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· MelanomaA Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
협력: 머크(MSD)
- 1/2상모집 중· Advanced CancerHighly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Renal Cell CarcinomaA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
리드: 머크(MSD)
- 1/2상모집 중· Advanced/Metastatic Solid TumorsADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중· Solid TumorsS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
협력: 머크(MSD)
- 1/2상모집 중단 (진행 중)· Platinum-refractory Ovarian CarcinomaOncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
협력: 머크(MSD)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.